Pulmonary hypertension is a common complication of systemic sclerosis and generally portends a very poor prognosis. Response to modern therapy for scleroderma-related pulmonary arterial ...

Results The task force agreed on 22 recommendations covering 8 clinical/organ domains including Raynaud’s phenomenon, digital ulcers, pulmonary arterial hypertension, scleroderma renal crisis, skin ...

PPF is identified by decline in lung function, worsening symptoms, and increased fibrosis on imaging, with variable criteria across studies. Risk factors for PPF include older age, male sex ...

gNew Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, USA hUniversity Medical Center, Comprehensive Pulmonary Hypertension Center and Interstitial Lung Disease ...

Pulmonary function tests (PFTs), including evaluation of forced vital capacity ... Despite being retrospective, our work aims to analyse the disease in its complexity, also considering the possible ...

Localized scleroderma (LS) is a complex disease characterized by a mixture of inflammation and fibrosis of the skin that, especially in the pediatric population, also affects extracutaneous tissues ...

The Scleroderma Research Foundation (SRF) — the country’s first and leading nonprofit investor in medical research into scleroderma — announced the lineup for its annual Cool Comedy • Hot ...

The presentation will review data supporting the efficacy of efzofitimod in pulmonary sarcoidosis ... patients with systemic sclerosis (SSc, or scleroderma)-related ILD. These forms of ILD ...

aTyr is currently investigating efzofitimod in the global Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis, a major form of ILD, and in the Phase 2 EFZO-CONNECT™ study in patients with ...